Cardiovascular risk reduction: The role of antihypertensive treatment

Norman M. Kaplan

Research output: Contribution to journalArticle

Abstract

The effects of antihypertensive drugs on mortality from stroke, coronary artery disease (CAD), and nonvascular causes have been studied in 14 trials involving more than 37,000 patients. In the treated patients, blood pressure was 5 to 6 mm Hg lower than that in placebo-treated patients, and whereas mortality from stroke was reduced by 42%, CAD mortality was reduced by only 14%. A major reason for this lack of effect on CAD mortality is apparently the adverse effects of the primary drugs used in these trials (diuretics and beta blockers) on glucose tolerance, lipid levels, and insulin resistance. The angiotensin-converting enzyme inhibitors favorably influence many CAD risk factors, and their use can be expected to reduce CAD mortality in patients treated for hypertension.

Original languageEnglish (US)
JournalAmerican Journal of Medicine
Volume90
Issue number2 SUPPL.1
StatePublished - 1991

Fingerprint

Risk Reduction Behavior
Antihypertensive Agents
Coronary Artery Disease
Mortality
Stroke
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Insulin Resistance
Placebos
Blood Pressure
Hypertension
Lipids
Glucose
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Cardiovascular risk reduction : The role of antihypertensive treatment. / Kaplan, Norman M.

In: American Journal of Medicine, Vol. 90, No. 2 SUPPL.1, 1991.

Research output: Contribution to journalArticle

@article{6d9ef8ffc32d432ca6a9ab0c4cc8bee7,
title = "Cardiovascular risk reduction: The role of antihypertensive treatment",
abstract = "The effects of antihypertensive drugs on mortality from stroke, coronary artery disease (CAD), and nonvascular causes have been studied in 14 trials involving more than 37,000 patients. In the treated patients, blood pressure was 5 to 6 mm Hg lower than that in placebo-treated patients, and whereas mortality from stroke was reduced by 42{\%}, CAD mortality was reduced by only 14{\%}. A major reason for this lack of effect on CAD mortality is apparently the adverse effects of the primary drugs used in these trials (diuretics and beta blockers) on glucose tolerance, lipid levels, and insulin resistance. The angiotensin-converting enzyme inhibitors favorably influence many CAD risk factors, and their use can be expected to reduce CAD mortality in patients treated for hypertension.",
author = "Kaplan, {Norman M.}",
year = "1991",
language = "English (US)",
volume = "90",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2 SUPPL.1",

}

TY - JOUR

T1 - Cardiovascular risk reduction

T2 - The role of antihypertensive treatment

AU - Kaplan, Norman M.

PY - 1991

Y1 - 1991

N2 - The effects of antihypertensive drugs on mortality from stroke, coronary artery disease (CAD), and nonvascular causes have been studied in 14 trials involving more than 37,000 patients. In the treated patients, blood pressure was 5 to 6 mm Hg lower than that in placebo-treated patients, and whereas mortality from stroke was reduced by 42%, CAD mortality was reduced by only 14%. A major reason for this lack of effect on CAD mortality is apparently the adverse effects of the primary drugs used in these trials (diuretics and beta blockers) on glucose tolerance, lipid levels, and insulin resistance. The angiotensin-converting enzyme inhibitors favorably influence many CAD risk factors, and their use can be expected to reduce CAD mortality in patients treated for hypertension.

AB - The effects of antihypertensive drugs on mortality from stroke, coronary artery disease (CAD), and nonvascular causes have been studied in 14 trials involving more than 37,000 patients. In the treated patients, blood pressure was 5 to 6 mm Hg lower than that in placebo-treated patients, and whereas mortality from stroke was reduced by 42%, CAD mortality was reduced by only 14%. A major reason for this lack of effect on CAD mortality is apparently the adverse effects of the primary drugs used in these trials (diuretics and beta blockers) on glucose tolerance, lipid levels, and insulin resistance. The angiotensin-converting enzyme inhibitors favorably influence many CAD risk factors, and their use can be expected to reduce CAD mortality in patients treated for hypertension.

UR - http://www.scopus.com/inward/record.url?scp=13644253029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13644253029&partnerID=8YFLogxK

M3 - Article

VL - 90

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2 SUPPL.1

ER -